In a shock move, AstraZeneca has ditched a plan to invest £450 million ($558 million) in a new vaccine manufacturing plant in ...

In the latest development, the European Commission has asked the EMA's human medicines committee, the CHMP, to take a look at ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the ...

Robert F Kennedy Jr's first confirmation hearing was a fractious affair, marked by tough questions about his prior ...

Vertex Pharma has secured FDA approval for its non-opioid pain drug suzetrigine, becoming the first new class of pain ...

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the ...

San Francisco-based Rad AI, which develops generative AI (GenAI) tools to improve radiology workflows, has raised $60 million ...

President Trump will continue to pursue the policy of Medicare pricing negotiation introduced by former President Biden's ...

The growing use of AI has opened new avenues for healthcare marketers, revolutionising how they approach new initiatives.

REGENXBIO is a longtime player in the gene therapy space, but one that’s yet to bring its own therapy to market (in the early ...

In a new pharmaphorum podcast with ZS Associates’ Sharon Karlsberg, principal and leader of oncology solutions, and Brandi ...

The scale of the decline in Veru's shares despite the positive result may reflect the amplified expectations of investors for ...